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Abstract: Allergic rhinitis (AR) is a prevalent disease with great morbidity and signiﬁ  cant societal 
and economic burden. Intranasal corticosteroids are recommended as ﬁ  rst-line therapy for patients 
with moderate-to-severe disease, especially when nasal congestion is a major component of symp-
toms. To compare the efﬁ  cacy and safety proﬁ  le of different available intranasal corticosteroids for 
the treatment of AR, it is important to understand their different structures and pharmacokinetic and 
pharmacodynamic properties. Knowledge of these drugs has increased tremendously over the last 
decade. Studies have elucidated mechanisms of action, pharmacologic properties, and the clinical 
impact of these drugs in allergic respiratory diseases. Although the existing intranasal corticosteroids 
are already highly efﬁ  cient, the introduction of further improved formulations with a better efﬁ  cacy/
safety proﬁ  le is always desired. Fluticasone furoate nasal spray is a new topical corticosteroid, with 
enhanced-afﬁ  nity and a unique side-actuated delivery device. As it has high topical potency and 
low potential for systemic effects, it is a good candidate for rhinitis treatment.
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Allergic rhinitis
Allergic rhinitis (AR) is an inﬂ  ammatory disease of nasal mucosa induced by an IgE-
mediated immune response. It is clinically deﬁ  ned as a symptomatic condition with 
four major symptoms: rhinorrhea, sneezing, nasal itching and obstruction (International 
Rhinitis Management Working Group 1994; Bousquet et al 2001).
Patients with AR can also experience fatigue, sleep disturbance, social function 
impairment, depressed mood, anxiety, learning and attention impairment, increased 
work or school absenteeism, and decreased work or school performance and produc-
tivity. The impact is made worse because of co-morbidities such as sinusitis, otitis 
media with effusion, allergic conjunctivitis, bronchial asthma, and dental disorders. 
Therefore, AR has a high morbidity with signiﬁ  cant societal and economic burden, 
due to direct and indirect costs (International Rhinitis Management Working Group 
1994; Yawn et al 1999; Crystal-Peters et al 2000; Leynaert et al 2000a; Bousquet et al 
2001; O’Connell 2004; Schoenwetter et al 2004).
AR has an estimated prevalence of 30% of the general population, which has been 
increasing, particularly in Western countries (The International Study of Asthma 
and Allergies I Childhood – ISAAC – Steering committee 1998; Upton et al 2000; 
Bousquet et al 2001). It is the most common chronic disorder in children and can be 
considered a major public health problem.
Allergic rhinitis and its impact on asthma
The ARIA (Allergic Rhinitis and its Impact on Asthma) guideline was published in 
2001, bringing some conceptual changes for rhinitis, such as the modiﬁ  cation of its 
classiﬁ  cation, and emphasizing the relationships between upper and lower airways 
(Figure 1; Bousquet et al 2001).Therapeutics and Clinical Risk Management 2008:4(2) 466
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AR can be classiﬁ  ed as perennial or seasonal (hay 
fever), depending on the timing and type of allergen 
involved in triggering the allergy. Patients with seasonal 
AR experience symptomatic exacerbations primarily dur-
ing pollen seasons. However, more recently, AR has also 
been classiﬁ  ed as intermittent or persistent, according 
to symptoms duration and frequency. This classiﬁ  cation 
also divides AR into mild or moderate/severe. Severity is 
measured as a short assessment of the impairment in the 
day-to-day life of the patient and not as a nasal symptom 
score (Bousquet et al 2001).
Nowadays, rhinitis and asthma are recognized as mani-
festations of one syndrome, the chronic allergic respiratory 
syndrome, also known as united airway disease. There is 
epidemiologic, immunopathologic, and clinical evidences 
that support an integrated view of these diseases and per-
mit an understanding of their interactions (Leynaert et al 
2000b; Bousquet et al 2001; Linneberg et al 2002; Togias 
2003). Almost all patients with asthma have rhinitis and 
the presence of severe rhinitis in patients with asthma is 
associated with worse asthma outcomes. AR is a risk fac-
tor for asthma development. Besides, beneﬁ  cial effects of 
nasal treatment on the lower airways have been reported, 
with fewer emergency service visits, fewer hospitalizations, 
and declining bronchial responsiveness (Crystal-Peters et al 
2002; Taramarcaz 2003).
Rhinitis treatment
Rhinitis treatment includes allergen avoidance, pharmaco-
therapy, and immunotherapy. Intranasal corticosteroids (INS) 
are recommended as ﬁ  rst-line therapy for patients with moder-
ate-to-severe AR, especially when nasal congestion is a major 
component of symptoms (International Rhinitis Management 
Working Group 1994; Bousquet et al 2001; van Cauwenberge 
et al 2005; Antonicelli et al 2007). INSs improve nasal con-
gestion more effectively and are more cost-effective than
nonsedating antihistamines, the most commonly prescribed 
AR medications (Craig et al 1998; Schoenwetter et al 2004; 
Price et al 2006). Oral antihistamines may be used concomi-
tantly with INS in more severe cases, in rhinitis exacerba-
tions, and in patients with ocular and skin symptoms that can 
occur, since atopic diseases are components of a systemic 
syndrome.
The major advantage of INS administration is that high 
concentrations of the drug, with rapid onset of action, can 
be delivered directly into the target organ, so that systemic 
effects are avoided or minimized. INS exert their anti-
inﬂ  ammatory effect through the inhibition of the production 
of many different cytokines, chemokines, enzymes, and cell 
adhesion molecules, after their interaction with intracellular 
glucocorticoid receptors.
To compare the efﬁ  cacy and safety proﬁ  le of different 
available INS for the treatment of AR, it is important to 
understand the different structures and their pharmacokinetic 
and pharmacodynamic properties (Corren 1999; Hübner et al 
2005). Pharmacokinetics are related to the concentration of 
a drug at the site of action over time, whereas pharmacody-
namics relate to drug’s concentration to its clinical effect. To 
determine the overall effect of a drug over time, a combina-
tion of pharmacokinetics/pharmacodynamics parameters has 
to be accomplished (Hübner et al 2005).
Receptor potency is a pharmacodynamic parameter 
and represents the binding ability of INS that is expressed 
by its receptor affinity compared with dexamethasone. 
Topical potencies of glucocorticoids have been most often 
compared with use of the Mckenzie assay, which assesses 
skin-blanching responses as a measure of cutaneous 
vasoconstriction (McKenzie 1962). Another recent method 
for comparing the biologic effects of topical corticosteroids 
has been to evaluate the inhibitory effects of various com-
pounds on the production of T lymphocyte-derived cytokines 
(English et al 1994; Umland et al 1997).
Some important pharmacokinetic parameters are: 
prodrug design, organ deposition, onset of action, lipophi-
licity, bioavailability, systemic clearance, protein binding, 
volume of distribution, device of administration, and nasal 
residence time.
A Cochrane Systematic Review compared the efﬁ  cacy 
and safety of ﬂ  uticasone propionate (FP) with beclometha-
sone dipropionate and budesonide in the treatment of chronic 
asthma. FP-treated participants had slightly better lung 
function, but with increased hoarseness and, probably, with 
a higher risk of sore throat (Adams et al 2007).
It is important to emphasize that decisions on the use 
of INS, especially in children, should be guided by the 
Figure 1 Allergic rhinitis and its impact on asthma (ARIA) aims.
To establish a guideline, proposing a standardized
management plan for allergic rhinitis.
To disseminate this guideline to general practitioners
and specialist physicians.
To emphasize allergic rhinitis impact on asthma.
To institute a multi-professional forum to discuss
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physician’s clinical experience and patients’ individual cir-
cumstances and preferences (Al Sayyad et al 2007).
Fluticasone furoate
Fluticasone furoate (FF) is a new, topical, intranasal, 
enhanced-affinity trifluorinated glucocorticoid, with 
potent anti-inﬂ  amatory activity and low systemic expo-
sure. FF is a synthetic ﬂ  uorinated corticosteroid having 
the chemical name (6α,11β,16α,17α)-6,9-difluoro-17-
{[(ﬂ  uoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-
oxoandrosta-1,4-dien-17-yl 2-furancarboxylate (Figure 2). 
The drug (GW685698X; VeramystTM; AvamysTM) comes 
in a nasal spray, as an aqueous suspension of micronized 
ﬂ  uticasone furoate for topical administration to the nasal 
mucosa by means of a metering, atomizing spray pump. 
Each actuation delivers 27.5 µg of FF in a volume of 50 µL 
of suspension that also contains 0.015% w/w benzalkonium 
chloride, dextrose anhydrous, edetate disodium, microcrys-
talline cellulose, carboxymethylcellulose sodium, polysor-
bate 80, and puriﬁ  ed water.
It has been developed for the treatment of AR in patients 
2 years of age and older and is administered via a unique, 
side-actuated device. FF is administered once daily and its 
recommended starting dose is 55 µg for children and 110 µg 
for adults and adolescents (FDA 2007; GlaxoSmithKline 
2007; McCormack and Scott 2007; RxList 2007).
Pharmacodynamic proﬁ  le
Fluticasone furonate has high receptor afﬁ  nity, with low equi-
librium dissociation constant (kd = 0.3 nmol/L) and with greater 
relative receptor afﬁ  nity (2989) than mometasone furoate 
(2244), ﬂ  uticasone propionate (1775), beclomethasone-17-
monopropionate (1345), ciclesonide active principle (1212), 
and budesonide (855) (Biggadike et al 2007).
Some in vitro studies showed that FF displayed greater 
potency than other corticosteroids in inhibiting tumor 
necrosis factor synthesis and action. It was also more 
potent in preventing damage to cultured human lung epi-
thelial cells by different stimulus. Experimental studies 
demonstrated more potent and faster anti-inﬂ  ammatory 
activity of FF than ﬂ  uticasone propionate (Salter et al 
2006, 2007).
FF displayed high selectivity for the glucocorticoid 
receptor in vitro and had no effect on the hypothalamic-
pituitary-adrenal (HPA) axis in children or adults during 
clinical trials (Pastel et al 2007; Salter et al 2007; Tripathy 
et al 2007). Laboratory tests that assess basal and dynamic 
function of HPA axis are frequently used to determine the 
systemic effects of INS.
Pharmakokinetic proﬁ  le
After single- and multiple-dose intranasal administra-
tion, plasma ﬂ  uticasone furoate concentrations are below 
the lower limit of quantiﬁ  cation in most patients (Allen 
et al 2007; Hughes et al 2007; Martin 2007). One study 
showed that only 2% of samples from patients receiving 
110 µg of FF had quantiﬁ  able plasma drug concentrations 
(Martin 2007).
Systemic bioavailability is determined by the sum of 2 
components, including the portion of the drug that is absorbed 
via the nasal mucosa plus the portion that is swallowed. 
The last one is the major route for circulation, what makes 
the ﬁ  rst-pass hepatic metabolism after drug absorption in the 
gastrointestinal tract very important.
Intranasal FF 880 µg was administered every 8 hours 
for 10 doses in healthy adult volunteers and the average 
absolute bioavailability was 0.5%. Oral bioavailability after 
2 mg single oral dose is 1.26% and elimination half-life after 
single intravenous dose is 15.1 hours (FDA 2007; Allen 
et al 2007).
FF was 99.4% bound to plasma protein in vitro and other 
research indicated extensive ﬁ  rst-pass metabolism of the 
absorbed drug (Salter et al 2006; Allen et al 2007). Protein 
binding is highly relevant because only the unbound free 
drug can exert an effect at the receptor site. As long as the 
corticosteroid is bound to a protein, it is unable to bind to 
its receptor. Clearance of FF is primarily by hydrolysis in 
the liver by the cytochrome P450 isozyme (CYP) 3A4 that 
converts the drug to the 17[beta]-carboxylic acid metabo-
lite (M10), which displays low glucocorticoid receptor 
agonist potency. The drug is excreted mainly in the feces, 
with only minor amounts in the urine (Hughes et al 2005; 
FDA 2007).
FF is a synthetic, lipophilic, corticosteroid (Biggadike et al 
2006). Agents highly lipophilic will demonstrate a higher and  Figure 2 Fluticasone furoate chemical structure.Therapeutics and Clinical Risk Management 2008:4(2) 468
Giavina-Bianchi et al
faster rate of uptake by the nasal mucous membrane, a higher 
level of retention within the nasal tissue, and an enhanced 
ability to reach the glucocorticoid receptor.
It has become widely recognized that many patients use 
INS on an as-need basis only, stopping medication when 
symptoms substantially abate. In support of this approach are 
recent studies demonstrating that intermittent use of INS is 
moderately effective in many patients (Juniper et al 1993). 
Therefore, onset of action can become an important feature 
of these drugs. In a perennial AR clinical trial, a statistically 
signiﬁ  cant difference between FF and placebo was ﬁ  rst noted 
at 24 hours after the ﬁ  rst dose for instantaneous total nasal 
symptom score and after 2 days for reﬂ  ective total nasal 
symptom score (Vasar et al 2007).
Drug formulation and delivery device
Drug’s formulation and delivery device may affect the 
efﬁ  cacy, tolerability, drug retention and deposition in nasal 
tissue, safety and patient preference and adherence to treat-
ment (Hübner et al 2005; Meltzer 2007). Optimization of 
formulation is one way to improve rhinitis treatment.
Additives and preservatives are included in INS formu-
lations to prevent bacterial growth, confer both taste and 
smell, absorb extra water, and maintain appropriate moisture 
levels. Some of these agents may irritate or dry nasal tissue 
and/or, rarely, lead to hypersensitivity. There is benzalko-
nium chloride, polysorbate, and carboxymethylcellulose in 
the FF formulation.
Benzalkonium chloride is a cationic surfactant used as a 
preservative in nasal solutions. Studies have showed that it 
can induce nasal mucociliary dysfunction, nasal irritation and 
hypersecretion, burning sensation, degenerative changes in 
supportive and olfactory cells, and squamous cell metaplasia 
(Steinsvag et al 1996; McMahon et al 1997; Hofmann et al 
2004; Meltzer 2007). However, the clinical impact of these 
effects on the nasal mucosa is unclear (Braat et al 1995; 
Bernstein 2000; Marple et al 2004; Verret and Marple 2005). 
Perhaps the nasal toxicity of benzalkonium chloride could 
be neutralized by nasal secretions and corticosteroids actions 
(Riechelmann et al 2004).
The polysorbates are nonionic surfactants and emulsify-
ing agents used as additives in drugs, food, shampoo, and 
lotions. Polysorbate 80 reversibly inhibited ciliary beat 
frequency in cultured human nasal epithelial cells and has 
been associated with allergy or sensitivity (Shelley et al 1995; 
Dimova et al 2003).
Carboxymethylcellulose is a thixotropic agent that 
increases nasal drug concentration, but also confers 
viscosity to INS solution, which is one of the reasons why 
the suspension must be shaken before use (Meltzer 2007). It 
exerts a drying effect on the nasal mucosa that may contribute 
to the incidence of epistaxis and it also has been involved in 
rare cases of allergic anaphylactic reactions (Patterson et al 
1995; Oppliger et al 2004).
Sensory attributes are an important factor in patient 
preference and adherence to INS treatment. Patients consider 
several sensory attributes during INS therapy: aftertaste, 
taste, smell, run out of nose, throat rundown (drip down), 
irritation, and urge to sneeze (Mahadevia et al 2004; Meltzer 
et al 2005; Meltzer 2007); sensation of moisture and soothing 
have been reported as good attributes. A study showed that 
benzalkonium chloride has a bitter taste that can be unpleas-
ant (Mahadevia et al 2004).
The FF delivery device is an easy-to-use aqueous pump 
spray that presents low risk for nasal tissue damage and with 
a new trigger mechanism that minimizes potential variation 
in the dose delivered (FDA 2007; Berger et al 2007). The 
device delivers a low spray volume, which minimizes the 
amount of drug available to run down the back of the throat 
or leak out the nose. It is suitable for use in young children 
aged 2 years and in the elderly.
Clinical trials
Therapeutic efﬁ  cacy of ﬂ  uticasone furonate in AR has been 
proven by double-blind, placebo-controlled, clinical trials 
that can be differentiated according to drug dosage, duration 
of treatment, age of patients, type of rhinitis, and end-points 
(Table 1).
A dose-ranging study in adolescents and adults with 
seasonal allergy to mountain cedar pollen established that 
the 110 µg dose provided the optimal beneﬁ  t-risk ratio. The 
signiﬁ  cant reduction in morning, predose, instantaneous total 
nasal symptom score (iTNSS) indicated, at least, 24-hour 
duration of efﬁ  cacy (Martin et al 2007).
FF was also superior to placebo for reductions in ocular 
symptoms of adults and adolescents suffering from seasonal 
and perennial AR (Stuebner 2006; Fokkens et al 2007a; 
Hampel et al 2007; Kaiser et al 2007; Ratner et al 2007; 
Vasar et al 2007). The mechanism by which it alleviates 
allergic conjunctivitis has yet to be fully elucidated. Possible 
mechanisms include: reduced nasal inﬂ  ammation resulting 
in reduced release of inﬂ  ammatory mediators and, hence, 
less activation of inﬂ  ammatory cells in the neighbouring 
tissues; improved drainage away from the eye down the 
nasolacrimal duct; and modulation of a naso-ocular neuro-
genic reﬂ  ex. It is unlikely that the observed effect results Therapeutics and Clinical Risk Management 2008:4(2) 469
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from systemic action of FF, since it has a low absolute 
bioavailability.
Oral antihistamines may be used concomitantly with 
INSs in patients for whom ocular symptoms are troublesome. 
However, in a meta-analysis of studies comparing INS with 
antihistamines, INS treatment was shown to reduce ocular 
symptoms as effectively as oral antihistamines (Weiner 
et al 1998).
Safety and tolerability
The severe adverse effects of chronic therapy with systemic 
corticosteroids are well documented. INS, at recommended 
doses, are generally not associated with long-term, clinically 
signiﬁ  cant, or irreversible adverse effects. However, many 
physicians and patients are still concerned about the potential 
adverse effects of these drugs and these feelings can reduce 
medication adherence, which is one of the biggest challenges 
that physicians tackle on a daily basis. If the health care pro-
vider can effectively communicate and convince the patient 
of the beneﬁ  t/risk ratio of steroids, patient outcomes can be 
improved (Rao and Apter 2005).
In a pooled analysis of clinical trials, the overall incidence 
of adverse events with intranasal ﬂ  uticasone furoate was 
similar to that with placebo, as was rate of withdrawal from 
therapy. The most common adverse events (incidence 1% 
in adolescents/adults or 3% in children, and with a higher 
frequency than placebo) were: headache, epistaxis, nasophar-
yngitis, pyrexia, pharyngolaryngeal pain, nasal ulceration, 
cough, and back pain (FDA 2007).
Treatment of adults and adolescents with FF for the 
long term (12 months) was likewise well tolerated, with 
no unusual or unexpected events. Epistaxis was the only 
adverse event occurring more frequently and with more 
severity among FF recipients (FDA 2007; Rosenblut et al 
2007). There was no evidence during long-term therapy of 
adverse events suggestive of clinically relevant systemic 
corticosteroid exposure.
There is consistent evidence that INS therapy in 
children can reduce short-term growth and growth veloc-
ity, especially during the ﬁ  rst year of treatment. However, 
studies suggest that usual doses of these drugs do not cause 
clinically relevant growth suppression or reduced ﬁ  nal 
height in the overall majority of patients (Brand 2001; 
Gulliver and Eid 2005). INS can reduce growth only 
after they become available systemically. FF systemic 
bioavailability is low and it had no effect on lower-leg 
growth rate assessed by knemometry in children (Gradman 
et al 2007).
Caution is necessary if co-administered with potent 
CYP3A4 inhibitors, such as ketoconazole and ritonavir, 
since the increased exposure to FF may increase the risk of 
systemic adverse effects (FDA).
There is low potential risk for systemic effects at recom-
mended doses of INS. When higher doses are administered, 
the physician should weight the beneﬁ  ts against the risks and 
consider the morbidity of uncontrolled rhinitis. To reduce 
any potential risk for systemic effects, the lowest effective 
dose of INS should be used.
Table 1 Double-blind, placebo-controlled, clinical trials of ﬂ  uticasone furonate in the treatment of allergic rhinitis
Clinical trial Type of rhinitis Age of patients Treatment duration End-points signiﬁ  cantly different
Martin et al 2007
Stanford et al 2007a
Stanford et al 2007b
Seasonal (mountain cedar) Adults and adolescents 2 weeks rTNSS, iTNSS, rTOSS, individual nasal 
symptom scores, RQLQ, NRQLQ
Kaiser et al 2007
Given et al 2007
Seasonal (ragweed) Adults and adolescents 2 weeks rTNSS, iTNSS, rTOSS, RQLQ
Hampel Jr et al 2007
van Bavel et al 2007
Ratner et al 2007
Seasonal (mountain cedar) Adults and adolescents 2 weeks rTNSS, iTNSS, rTOSS, RQLQ
Fokkens et al 2007a
Fokkens et al 2007b
Seasonal (grass) Adults and adolescents 2 weeks rTNSS, iTNSS, rTOSS, RQLQ
Meltzer et al 2007a
Meltzer et al 2007b
Seasonal Children 2 weeks rTNSS, iTNSS
Nathan et al 2007 Perennial Adults and adolescents 4 weeks rTNSS, iTNSS
Vasar et al 2007 Perennial Adults and adolescents 6 weeks rTNSS, iTNSS, rTOSS, iTOSS
Maspero et al 2007 Perennial Children 4 weeks rTNSS, iTNSS
Instantaneous scores indicated the patients’ level of symptoms at the time of recording the score, just prior to taking the next medication’ dose, each day, as a measure of 
24-h duration of action. Reﬂ  ective scores were based on the symptoms experienced by the patient during the previous 12 h (morning and evening, the scores summed and 
averaged to give the daily reﬂ  ective score).
Abbreviations: rTNSS, reﬂ  ective total nasal symptom score; iTNSS, instantaneous total nasal symptom score; rTOSS, reﬂ  ective total ocular symptom score; iTOSS, instan-
taneous total ocular symptom score; RQLQ, rhinoconjunctivitis quality of life questionnaire; NRQLQ, nocturnal rhinoconjunctivitis quality of life questionnaire.Therapeutics and Clinical Risk Management 2008:4(2) 470
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Conclusion
The role of INS in the treatment of AR is well established. 
They are proven to be efﬁ  cacious and are recommended as 
ﬁ  rst-line therapy for individuals with persistent moderate/
severe rhinitis.
Knowledge about INS has increased tremendously over 
the last decade. Studies have elucidated mechanisms of 
action, pharmacologic properties, and the clinical impact 
of these drugs in allergic respiratory diseases. Although the 
existing ICS are already highly efﬁ  cient, the introduction of 
further improved formulations with a better efﬁ  cacy/safety 
proﬁ  le is always desired.
FF nasal spray is a new topical corticosteroid, with 
enhanced-affinity and a unique side-actuated delivery 
device, which is effective in improving nasal symptoms of 
AR. Signiﬁ  cant improvement in ocular symptoms and in 
quality of life was also demonstrated. Its low oral bioavail-
ability and high plasma protein binding minimize systemic 
adverse effects. A potentially prolonged nasal retention time 
may further enhance the efﬁ  cacy of FF, which may allow 
for a once-daily dosing regimen in adults, adolescents, and 
children.
FF with high topical potency and low potential for sys-
temic effects is a good candidate for rhinitis treatment. As 
expected for all new drugs, long-term safety and efﬁ  cacy 
studies are required, which can establish the potential modi-
ﬁ  cation of AR course.
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